CERS Cerus Corp: רווח למניה ב-12 החודשים האחרונים

Risks for Cerus Corporation (CERS) are linked to the high cost of clinic equipment and shifts in insurance payouts, which is confirmed by the linear price action on the chart, where EPS stands at 55.80. Cerus Corporation (CERS) relies on a global reagent supply network to maintain high margins. The business maintains its leadership through a unique blood purification technology that creates significant barriers to entry for new market players.
פילוחי מדדים פיננסיים ומדדי שוק עבור Cerus Inc (CERS)

This metric measures the dynamics of net income per share over a rolling year, revealing the actual speed of business scaling. By analyzing the EPS YoY growth rate (trailing 12 months), an investor determines the sustainability of capitalization amid compressing market multiples. Any deceleration in this trend signals hidden risks, even with stable revenues. For Cerus Corporation (CERS), such a metric confirms the efficiency of the monopoly INTERCEPT system and the long-term dependence of hospitals on its technologies.